Opendata, web and dolomites



Total Cost €


EC-Contrib. €






 RESTORE project word cloud

Explore the words cloud of the RESTORE project. It provides you a very rough idea of what is the project "RESTORE" about.

accessibility    traumatic    nervous    cancer    biobanking    inflammatory    trials    cure    safeguarding    remaining    self    innovative    suffering    autoreactive    immune    efficacy    balance    therapy    drive    practicality    clinical    radiological    multidisciplinary    centers    place    inducing    safety    network    safely    disabling    tolerance    antigen    clinic    outcome    restoring    neurodegeneration    capacity    centralized    disease    people    multiple    therapeutic    action    nl    neurological    es    correlates    patient    reducing    thereby    data    renewal    damaging    patients    500    dendritic    neuronal    reactions    adults    repair    team    context    efforts    approvals    ger    central    pathogens    cell    young    neurodegenerative    countries    compare    additional    breakthrough    bm1305    coordinated    collaborative    immunity    mri    immunomonitoring    center    first    monitoring    sclerosis    inflammation    lives    hypothesize    chronic    cells    joins    consented    protective    proof    regulatory    ms    toldc    healthcare    assaults    restore    untreatable    single   

Project "RESTORE" data sheet

The following table provides information about the project.


Organization address
address: PRINSSTRAAT 13
postcode: 2000

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website
 Total cost 5˙357˙032 €
 EC max contribution 5˙357˙032 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) coordinator 911˙176.00
2    INSTITUT CATALA DE LA SALUT ES (BARCELONA) participant 1˙170˙212.00
3    Stichting Sanquin Bloedvoorziening NL (Amsterdam) participant 911˙250.00
5    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 625˙000.00
6    ICOMETRIX NV BE (LEUVEN) participant 530˙500.00
8    STICHTING LYGATURE NL (UTRECHT) participant 185˙000.00


 Project objective

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which no cure is currently available. It is the leading cause of non-traumatic disabling neurological disease in young adults with more than 500,000 people affected in Europe. As chronic inflammatory processes drive the neurodegeneration, we hypothesize that improved clinical outcome can be achieved by restoring the balance between inflammation and the remaining capacity of neuronal self-renewal. In this context, cell therapy that specifically targets the damaging immune reactions that cause MS, thereby reducing the autoreactive, inflammatory assaults in MS without affecting protective immunity against pathogens and cancer, can be a promising approach to allow for more repair. Recently, we set-up a collaborative network of European centers working in cell therapy (COST Action BM1305). From this, a multidisciplinary team from four different EU countries (B, ES, NL and GER) with two additional partners now aims to safely reach the next level of testing and joins efforts to bring antigen-specific cell therapy for MS to the clinic. Our objectives are to evaluate safety, clinical practicality and demonstrate first proof-of-principle of therapeutic efficacy of antigen-specific tolerance-inducing dendritic cells (tolDC) in MS patients in two single-center clinical trials. All regulatory approvals are already in place. Coordinated patient monitoring and centralized MRI monitoring, including radiological correlates of neurodegeneration, and immunomonitoring will enable us to directly compare results between trials and enable consented biobanking, data safeguarding and accessibility to support future efforts in the field of MS therapy. ReSToRe focuses on the advancement of an innovative cell therapy approach with the potential to improve the lives of patients suffering from MS, a currently untreatable disease. This would represent a breakthrough for healthcare in MS.


List of deliverables.
Certificates of clinical training Documents, reports 2019-08-30 14:59:36

Take a look to the deliverables list in detail:  detailed list of RESTORE deliverables.


year authors and title journal last update
List of publications.
2019 Willekens B, Presas-Rodríguez, Mansilla M, Derdelinckx J, Lee W-P, Nijs G, De Laere M, Wens I, Cras P, Parizel PM, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye M, Navarro-Barriuso J, Teniente-Serra A, Quirant-Sánchez B, López-Díaz de Cerio A, Inogés S, Prósper F, Kip A, Verheij H, Gross CC, Wiendl H, van Ham SM, ten Brinke A, Barriocanal AM, Massuet-Vilamajó A, Hens N, Berneman Z,
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonized study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
published pages: , ISSN: 2044-6055, DOI:
BMJ Open accepted for publication 23/7/2 2019-09-05
2018 Barbara Willekens, Nathalie Cools
Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis
published pages: 401-410, ISSN: 1172-7047, DOI: 10.1007/s40263-018-0518-4
CNS Drugs 32/5 2019-09-05
2019 Anja ten Brinke, Marc Martinez-Llordella, Nathalie Cools, Catharien M. U. Hilkens, S. Marieke van Ham, Birgit Sawitzki, Edward K. Geissler, Giovanna Lombardi, Piotr Trzonkowski, Eva Martinez-Caceres
Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective
published pages: , ISSN: 1664-3224, DOI: 10.3389/FIMMU.2019.00181
Frontiers in Immunology 10 2019-09-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESTORE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESTORE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More